RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01
| Change in Registrants Certifying Accountant |
On November 22, 2016, the Company dismissed BDO LLP
(BDO) as the Companys independent registered
public accounting firm, effective immediately. On November 22,
2016, the Company appointed Marcum LLP (Marcum)
as the Companys new independent registered public accounting firm
effective as of November 22, 2016.
The Audit Committee of the board of directors of the Company
approved the dismissal of BDO and the appointment of Marcum.
The reports of BDO on the Companys financial statements for each
of fiscal years ended June 30, 2016 and 2015 did not contain an
adverse opinion or a disclaimer of opinion, nor were they
qualified or modified as to uncertainty, audit scope or
accounting principle.
During the fiscal years ended June 30, 2016 and 2015, and the
subsequent interim period through November22, 2016, there were no
disagreements (as that term is defined in Item304(a)(1)(iv) of
Regulation S-K and related instructions) between the Company and
BDO on any matter of accounting principles or practices,
financial statement disclosure or auditing scope or procedures
which disagreements, if not resolved to the satisfaction of BDO
would have caused BDO to make reference thereto in their reports
on the financial statements for such years.
The Company provided BDO with a copy of the disclosures it is
making in this Current Report on Form 8-K and requested that BDO
furnish the Company with a letter addressed to the Securities and
Exchange Commission stating whether it agrees with the statements
contained herein. A copy of BDOs letter, dated November 28, 2016,
is filed as Exhibit 16.1 to this Current Report on Form 8-K.
During the fiscal year ended June 30, 2016 and the period from
July1, 2016 through November 28, 2016, neither the Company, nor
anyone acting on its behalf, consulted with Marcum regarding
(i)the application of accounting principles to a specified
transaction, either completed or proposed, or the type of audit
opinion that may be rendered on the Companys financial
statements, and Marcum did not provide either a written report or
oral advice to the Company that was an important factor
considered by the Company in reaching a decision as to the
accounting, auditing or financial reporting issue, or (ii)any
matter that was either the subject of a disagreement (as defined
in Item304(a)(1)(iv) of Regulation S-K and the related
instructions) or a reportable event (as described in
Item304(a)(1)(v) of Regulation S-K).
| Item 9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
The exhibits listed in the following Exhibit Index are filed as
part of this Current Report on Form 8-K.
| Exhibit No. | Description |
| 16.1 |
Letter from BDO LLP dated November 28, 2016 |
About RASNA THERAPEUTICS, INC. (OTCMKTS:RASP)
Rasna Therapeutics, Inc., formerly Active With Me Inc., creates online resources that offer travelers information on activity-based travel. The Company’s Website focuses on offering third-party content and information to visitors in their activity of choice. The Company’s Website also focuses on offering links to clubs and organizations. The Company is in development-stage. Rasna DE is the subsidiary of the Company. Rasna DE is engaged in modulating the molecular targets nucleophosmin gene (NPM1) and lysine (K)-specific demethylase 1A (LSD1), which are implicated in the disease progression of leukemia and lymphoma. The Company focuses on performing preclinical research on NPM1 and LSD1. As of June 30, 2016, the Company had not generated any revenues. RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) Recent Trading Information
RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) closed its last trading session 00.00 at 1.55 with shares trading hands.